The management of type 2 diabetes (T2D) and obesity has been revolutionised by glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (e.g., dulaglutide, liraglutide, semaglutide), and, more recently, dual agonists of GLP‐1 and glucose‐dependent insulinotropic polypeptide (GIP) receptors, such as tirzepatide. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.